Articles On Telix Pharmaceuticals (ASX:TLX)

ASX 200 healthcare share Telix Pharmaceuticals Ltd (ASX: TLX) has had a stellar month. The Telix Pharmaceuticals share price has soared 53% from $7.01 at market close on 3 April to $10.745 at the time of writing. For perspective, the S&am...

The S&P/ASX 200 Index (ASX: XJO) plummeted on Tuesday, dropping 0.92% to finish the session at 7,267.4 points. Its day in the red came amid the Reserve Bank of Australia (RBA) board’s May meeting, wherein it hiked interest rates once...

MELBOURNE, Australia, May 2, 2023 /PRNewswire/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illucc...

The ASX jumped half a percent, tracking moves in New York on Friday Three major decisions by central banks this week Judo Capital upgrades its net interest margin guidance for H2    The ASX 200 index rose to by 0.5% on Tuesday as it track...

The S&P/ASX 200 Index (ASX: XJO) has started the week in a positive fashion. In afternoon trade, the benchmark index is currently up 0.5% to 7,343.3 points. Four ASX shares that are climbing more than most today are listed below. Her...

Telix Pharmaceuticals (TLX) reveals new “positive” results from its phase III ZIRCON study of its TLX250-CDx imaging agent in clear cell renal cell carcinoma (ccRCC) TLX says the study shows the “high value” of its agent in detecting cc...

MELBOURNE, Australia, May 1, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuxi...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Telix Pharmaceuticals (TLX) expands its artificial intelligence (AI) capability through the acquisition of Vienna-based Dedicaid, a spin-off of Medical University Vienna Telix says Dedicaid’s core asset, a clinical decision support softw...

Stock in S&P/ASX 200 Index (ASX: XJO) biopharma company Telix Pharmaceuticals Ltd (ASX: TLX) is in the red on news of a major artificial intelligence (AI) acquisition. The developer of diagnostic and therapeutic radiopharmaceuticals ha...

The ASX is on Thursday expected to follow the US Dow Jones index, which declined overnight following another slump in the banking sector. The dip comes from troubles surrounding the First Republic Bank, which has seen its shares fall mor...

After starting off deep in the red, the S&P/ASX 200 Index (ASX: XJO) regained some ground to close 0.08% lower at 7,316.3 points. Its wobbly performance came amid the release of the latest Australian consumer price index (CPI) data, co...

The S&P/ASX 200 Index (ASX: XJO) closed the week in the red, falling 0.43% in Friday’s session to close at 7,330.4 points. That leaves it 0.42% lower than it was this time last week. Weighing the index down today were its two largest...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and is on course to end the week with a decline. In afternoon trade, the benchmark index is down 0.4% to 7,335.4 points. Four ASX shares that are not letting that hol...

ASX health stocks fall 0.32% in the past five days, despite rise in broader markets Neuren Pharmaceutical announces its DAYBUE drug officially available in US to treat Rett Syndrome Impedimed quarterly results in line with expectations wit...

Highlights: The Australian benchmark index S&P/ASX 200 index, has decreased by 2.64% in the last one-year period. On 20 April, SILK Australia Limited (ASX: SLA) managed to hit its 52-week, closing the trading session at AU$3.000, i...

The S&P/ASX 200 Index (ASX: XJO) traded relatively flat for most of Thursday, finishing the session 0.04% lower at 7,362.2 points. It came on a dismal performance by the S&P/ASX 200 Materials Index (ASX: XMJ). The mining sector tu...

Australian radiopharmaceutical company Telix (ASX:TLX) has delivered its first $100 million revenue quarter with soaring growth in the US.

The ASX ended the day in the green, but Asian markets didn’t quite cross the line. The ASX 200 closed up 5.3 points or 0.07 per cent to 7365.5 points. In the green Healthcare stock Telix Pharmaceuticals (TLX) was the top-performing...

The S&P/ASX 200 Index (ASX: XJO) had a rocky session on Wednesday, ultimately closing 0.07% higher at 7,365.5 points. Today’s top-performing sector was the S&P/ASX 200 Materials Index (ASX: XMJ). It soared 1.1%. Unfortunately, it...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a tiny gain. At the time of writing, the benchmark index is up a fraction to 7,362.2 points. Four ASX shares that are climbing more than most today are listed...

ASX 200 stock Telix Pharmaceuticals Ltd (ASX: TLX) has been having a top run on the market lately. Telix shares have risen nearly 32% in a month and are currently fetching $9.30. In today’s trade, Telix shares are up 4.44%. In contrast,...

Trawling through shares in the S&P/ASX 200 Index (ASX: XJO), we can at times forget what actually creates wealth for shareholders in the long run. While the share price moves arbitrarily in the short term, the decisions on how to inve...

The ASX 200 ended Tuesday 0.3 per cent lower at 7360 points after struggling to stage a midday comeback. Minutes from the Reserve Bank’s last meeting revealed an April rates hike was very much on the cards before its decision to pause....

ShareCafeASX recoups some earlier losses to close 0.29% lower by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.29 per cent lower at 7,360.20, primarily due to a 1.9 per cent decline in the energy sector, with Woodside (ASX:W...

The S&P/ASX 200 Index (ASX: XJO) traded in the red on Tuesday, falling 0.29% to close at 7,360.2 points. Weighing it down was the S&P/ASX 200 Energy Index (ASX: XEJ). The energy sector fell 1.9% on the back of a rough night for oil...

The ASX slumped by 0.4% today as the RBA released its April minutes Core Lithium jumped 8pc after increasing its MRE BlackRock ditched its 60/40 strategy   Local shares fell 0.4% on Tuesday after the RBA minutes revealed the central bank...

It’s been a pretty depressing day for ASX shares and the All Ordinaries Index (ASX: XAO) so far this Tuesday. At the time of writing, the All Ords has slipped by 0.4%, dragging the Index back below 7,550 points. But not all All Ords shares...

Telix (ASX:TLX) says olaratumab, an antibody licensed from Eli Lilly, has demonstrated proof-of-concept in a preclinical study investigating its delivery of diagnostic and therapeutic radiation to tumours.

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March...

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Comp...

The S&P/ASX 200 Index (ASX: XJO) ended the week on a high, rising 0.51% to finish the session at 7,361.6 points – its highest close since early March. That also leaves it 1.98% higher week-on-week. It followed a strong session over o...

MELBOURNE, Australia, April 11, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a...

The S&P/ASX 200 Index (ASX: XJO) put on a rocky performance on Wednesday, eventually closing the session 0.02% higher at 7,237.2 points. The fall came as Reserve Bank of Australia (RBA) governor Philip Lowe addressed the National Pres...

In a recent memo to investors, Wilsons equity strategist Rob Crookston pointed out how there are many similarities between 2023 and 2019. In both those years the economy was slowing. In 2019, the Reserve Bank of Australia and US Federal re...

The ASX swung into positive after the release of monthly CPI data Australia’s inflation has declined to 6.8% in February from 7.4% in January SBF allegedly bribed Chinese officials with $40 million in cryptos   Local shares traded lower b...

ShareCafeGains from Energy and Materials boost ASX: Aus shares close 1% higher by Peter Milios   At the closing bell, the S&P/ASX 200 was 1.04 per cent higher at 7,034.10, with the Energy sector leading the gains and surging 4.1 per cen...

The S&P/ASX 200 Index (ASX: XJO) started the week out on the right foot today, lifting 0.1% to close Monday’s session at 6,962 points. The major news on investors’ minds this morning came from overseas, however. Stock in Germany’...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

The medical imaging market size globally is forecast to reach $68.8 Billion by 2030 Several ASX health imaging stocks are establishing strong footholds and niches in sector Micro-X branching out from the medical sphere with its bomb detect...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

Following FY22 results for Telix Pharmaceuticals brokers remain Buy-rated in light of an extensive pipeline of new products under development. -Brokers retain bullish commentary on Telix Pharmaceuticals -Jarden expects positive operational...

Saturday March 11 was a typical balmy autumnal afternoon in Melbourne, but Neuren (ASX:NEU) chief Jon Pilcher was despondent as he awaited news from the company’s US partner Acadia on whether the US Food and Drug Administration (FDA) had ap...

ASX health stocks fall 1.5% in the past five days, broader markets fall on global banking concerns Neuren Pharmaceuticals has soared 60% after FDA approves its drug for Rett’s syndrome  Antisense starts chronic monkey toxicology study of A...

The ASX 50 drops 1.50% and ASX 200 loses 1.46% ABS say unemployment rate fell to 3.5% for February following two months of consecutive falls Labour force data is one of four economic data points the RBA uses when looking at rate hikes   A...

Telix Pharmaceuticals (TLX) has landed US FDA approval to image patients with metastatic prostate cancer with its Illuccix imaging agent The FDA has approved a supplementary new drug application (sNDA) for Illuccix, enabling TLX to ident...

Telix Pharma gets FDA approval Prescient shows good data from Phase 1b clinical trial Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas   Telix Pharma (ASX:TLX) announced the US FDA has a...

MELBOURNE, Australia, March 14, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girent...

The S&P/ASX 200 Index (ASX: XJO) regained some of its Monday losses today, closing 0.47% higher at 7,258.4 points. Leading the charge were energy stocks, with the S&P/ASX 200 Energy Index (ASX: XEJ) gaining 1.5% with the Woodside E...

The final day of earnings season has seen a number of ASX 200 shares release their latest results. Some of these results have gone down well with investors and some have been received less enthusiastically. Three ASX 200 shares that are ma...